GeoVax Labs vs Cartesian Therapeutics
Cartesian Therapeutics reported revenue of $3 million in fiscal 2025, about the same as GeoVax Labs' $2 million in fiscal 2025. GeoVax Labs' revenue fell 37.1% in its latest year, and Cartesian Therapeutics' fell 92.8%. GeoVax Labs had an operating margin of -869.3%, against -5127.1% at Cartesian Therapeutics. Free cash flow was −$22 million at GeoVax Labs and −$79 million at Cartesian Therapeutics.
Side by side
| GeoVax Labs | Cartesian Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $3M |
| Revenue growth | −37.1% | −92.8% |
| Revenue growth a year, last 5 years | 6.8% | −29.9% |
| Gross margin | — | — |
| Operating margin | −869.3% | −5,127.1% |
| Net margin | −862.3% | −4,658.6% |
| Free cash flow | −$22M | −$79M |
| Free cash flow margin | −863.8% | −2,838.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 361.9% | 49.6% |
| Last close | $1.91 | $5.89 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $205,800, sold $258,683 |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
GeoVax LabsCartesian Therapeutics
Operating margin
Percent of revenue
GeoVax LabsCartesian Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
GeoVax LabsCartesian Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the GeoVax Labs and Cartesian Therapeutics pages.